FierceBiotech14h
GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market
The study enrolled 238 people with primary biliary cholangitis (PBC) and cholestatic pruritus, a medical term for relentless ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
Medpage Today on MSN4d
Managing Primary Biliary Cholangitis Progression and Symptoms
Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
pharmaphorum10h
GSK drug raises hopes for patients with PBC itch
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
GSK reports positive Phase 3 results for linerixibat in PBC itching
GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...
Medpage Today on MSN4d
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
The Pharma Letter7h
Linerixibat shows positive Phase III results in PBC, says GSK
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
GSK's linerixibat meets primary endpoint
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
Business Insider17h
GSK announces phase III trial of linerixibat met primary endpoint
in adults with cholestatic pruritus associated with primary biliary cholangitis, a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat resulting in an improvement in itch ...